DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

Information source: VA Medical Center, Houston
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alzheimer's Disease; Hypogonadism

Intervention: AndroGel (Solvay Pharmaceuticals) (Drug)

Phase: N/A

Status: Completed

Sponsored by: VA Medical Center, Houston

Official(s) and/or principal investigator(s):
Robert S. Tan, MD, Principal Investigator, Affiliation: Michael E. DeBakey VA Medical Center, Houston, TX


Treatment with testosterone can improve performance on tests of spatial ability in men with low testosterone levels and Alzheimer's disease. Improved performance on these tests may mean an improved ability to get around in one's environment without getting lost or injured. This could have a positive impact on both patients and those who care for them. We will investigate what areas of the brain are involved in these improvements in spatial ability. This will be done using a PET scan, which creates a 3-dimensional image of the brain that can allow us to see how the brain functions.

Clinical Details

Official title: A Pilot Study of the Effect of Testosterone on Cerebral Glucose Metabolism in Hypogonadal Males With Alzheimer's Disease

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Calculated difference image of pre-treatment and on-treatment PET scans.

Secondary outcome: Change in cognitive function at 8-week intervals over a 6-month period.

Detailed description: Volunteers will be treated with a prescription testosterone gel applied to the shoulder or other body area each day. This treatment will continue for 6 months. Subjects will undergo a PET scan at the beginning of the study and after approximately 2 months of treatment. Subjects will undergo some cognitive testing throughout the study.


Minimum age: 55 Years. Maximum age: N/A. Gender(s): Male.


Inclusion Criteria:

- Alzheimer's disease diagnosis, based on Diagnostic and Statistical Manual of Mental

Disorders (5th ed.; DSM-V)

- Total testosterone < 300 ng/dL and/or calculated free testosterone < 50 pg/ml

- Sufficient English to perform cognitive testing

- Stable on concomitant medications for 1 month prior to starting study

Exclusion Criteria:

- history of prostate cancer

- history of breast cancer

- gonadal endocrine disorders

- current major psychiatric illness (excluding depression)

- significant uncontrolled systemic illness

- recent myocardial infarction (within 6 months)

- renal or hepatic disease, sleep apnea

- history of alcoholism or substance abuse within the past year

- history of head injury with loss of consciousness greater than 1 hour

- testosterone or other androgen treatment within past 3 months

- history of taking other drugs that might interfere with the results of the study (ie,

spironolactone, cimetidine, antiandrogens, estrogens, p450 enzyme inducers, barbiturates)

- symptomatic BPH: prostatic symptoms, prostatic masses or induration on rectal


- prostate specific antigen (PSA) >4. 0 mg/mL

- hemoglobin > 17 mg/dL

- generalized skin disease that could affect the absorption of testosterone gel (ie,


- potentially agitated or uncooperative for procedures

Locations and Contacts

Michael E. DeBakey VA Medical Center, Houston, Texas 77030, United States
Additional Information

Starting date: April 2007
Last updated: August 18, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017